Quick Answer
FILANA THERAPEUTICS, INC. reported Cash And Cash Equivalents At Carrying Value of $95.50 million for the year ending 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -25.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from FILANA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $66.77 million | Q3 2010: $106.29 million | Q1 2011: $54.89 million | Q2 2011: $62.83 million | Q3 2011: $71.71 million | Q1 2012: $73.78 million | Q2 2012: $79.02 million | Q3 2012: $88.24 million | Q1 2013: $51.59 million | Q2 2013: $51.55 million | Q3 2013: $49.73 million | Q1 2014: $45.85 million | Q2 2014: $44.58 million | Q3 2014: $42.05 million | Q1 2015: $37.25 million | Q2 2015: $36.35 million | Q3 2015: $33.99 million | Q1 2016: $26.61 million | Q2 2016: $24.63 million | Q3 2016: $21.21 million | Q1 2017: $17.26 million | Q2 2017: $14.07 million | Q3 2017: $11.92 million | Q1 2018: $10.73 million | Q2 2018: $9.61 million | Q3 2018: $20.44 million | Q1 2019: $19.13 million | Q2 2019: $18.53 million | Q3 2019: $17.80 million | Q4 2019: $23.08 million | Q1 2020: $25.60 million | Q2 2020: $25.25 million | Q3 2020: $24.07 million | Q1 2021: $282.19 million | Q2 2021: $278.25 million | Q3 2021: $241.52 million | Q1 2022: $209.69 million | Q2 2022: $197.23 million | Q3 2022: $174.66 million | Q1 2023: $187.47 million | Q2 2023: $168.44 million | Q3 2023: $142.35 million | Q1 2024: $124.17 million | Q2 2024: $207.29 million | Q3 2024: $148.98 million | Q1 2025: $117.33 million | Q2 2025: $112.38 million | Q3 2025: $106.08 million.
- Over the full 18 years of available data (2008 to 2025), FILANA THERAPEUTICS, INC.'s Cash And Cash Equivalents At Carrying Value has declined by 37.6%.
- Historical annual values: Fiscal year 2025: $95.50 million | Fiscal year 2024: $128.57 million | Fiscal year 2023: $121.14 million | Fiscal year 2022: $201.02 million | Fiscal year 2021: $233.44 million | Fiscal year 2020: $93.51 million | Fiscal year 2019: $23.08 million | Fiscal year 2018: $19.81 million | Fiscal year 2017: $10.48 million | Fiscal year 2016: $16.62 million | Fiscal year 2015: $31.30 million | Fiscal year 2014: $40.59 million | Fiscal year 2013: $48.59 million | Fiscal year 2012: $49.36 million | Fiscal year 2011: $73.14 million | Fiscal year 2010: $4.80 million | Fiscal year 2009: $35.79 million | Fiscal year 2008: $153.16 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: